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Abstract
Background: Local inflammation associated with solid tumors commonly results from factors released by tumor cells and
the tumor stroma, and promotes tumor progression. Cancer associated fibroblasts comprise a majority of the cells found in
tumor stroma and are appealing targets for cancer therapy. Here, our aim was to determine the efficacy of targeting cancer
associated fibroblasts for the treatment of metastatic breast cancer.
Methodology/Principal Findings: We demonstrate that cancer associated fibroblasts are key modulators of immune
polarization in the tumor microenvironment of a 4T1 murine model of metastatic breast cancer. Elimination of cancer
associated fibroblasts in vivo by a DNA vaccine targeted to fibroblast activation protein results in a shift of the immune
microenvironment from a Th2 to Th1 polarization. This shift is characterized by increased protein expression of IL-2 and IL-7,
suppressed recruitment of tumor-associated macrophages, myeloid derived suppressor cells, T regulatory cells, and
decreased tumor angiogenesis and lymphangiogenesis. Additionally, the vaccine improved anti-metastatic effects of
doxorubicin chemotherapy and enhanced suppression of IL-6 and IL-4 protein expression while increasing recruitment of
dendritic cells and CD8
+ T cells. Treatment with the combination therapy also reduced tumor-associated Vegf, Pdgfc, and
GM-CSF mRNA and protein expression.
Conclusions/Significance: Our findings demonstrate that cancer associated fibroblasts promote tumor growth and
metastasis through their role as key modulators of immune polarization in the tumor microenvironment and are valid
targets for therapy of metastatic breast cancer.
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Introduction
The solid tumors of multiple cancers, including that of the
breast, are often associated with local inflammation [1]. In fact,
cancer-related inflammation has recently been proposed as the
seventh hallmark of cancer [2]. During normal physiological
processes, such as wound healing, inflammatory cells recruited to
the site of injury support tissue repair through secretion of growth
factors and cytokines that promote tissue remodeling and
angiogenesis [3]. Importantly, inflammation subsides once the
tissue has been repaired [3]. In contrast, the normal controls
regulating inflammation are circumvented during neoplastic
progression which has resulted in the characterization of tumors
as wounds that never heal [4].
Solid tumors are multi-cellular tissues comprised of tumor cells
and stromal cells, including fibroblasts, endothelial cells and
inflammatory cells [5]. Recent studies focusing on cancer-
associated fibroblasts (CAFs) have begun to uncover their
prominent role in promoting tumor growth and progression [6].
In contrast to resting fibroblasts, CAFs possess an activated
phenotype and can be identified by their expression of vimentin,
desmin, a-smooth-muscle actin and fibroblast activation protein
(FAP) [7]. CAFs are further characterized by their production of
growth factors and extracellular matrix proteins that promote
proliferation and survival of tumor cells [6]. Additionally, up to
80% of stromal fibroblasts in breast cancer are thought to possess
this activated phenotype [6]. However, compared to transformed
tumor cells, CAFs are considerably more genetically homogeneous
and thus represent an attractive target for cancer therapy [8].
We have previously reported that a DNA vaccine targeted to
Fibroblast Activation Protein (pFAP) can specifically and effec-
tively eliminate CAFs in vivo and suppress primary tumor growth of
non-metastatic murine colon and breast cancers [9]. FAP, also
known as Seprase, is a type II transmembrane glycoprotein
belonging to the serine protease family and was first isolated from
human malignant melanoma [10]. FAP expression has since been
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including breast carcinomas, and their metastases [11]. Addition-
ally, the expression pattern of FAP was shown to be highly cancer-
specific and localized to stromal fibroblasts in solid tumors [12].
Similarly, we have also observed stroma-specific expression of FAP
in murine carcinomas [9]. Importantly, we have also previously
shown that vaccination of mice with pFap did not impair wound
healing or cause toxicity in normal tissues [9].
In the current study our aim was to determine the efficacy of
our vaccine for suppression of spontaneous breast cancer
metastasis and to further investigate the broader cellular effects
of our vaccine on the tumor microenvironment (TME). Our
finding here demonstrate that CAFs are key modulators of the
immune TME and that their elimination in vivo has profound
effects on immune polarization in the TME. Importantly, this
modulation of immune polarization is associated with decreased
tumor angiogenesis, lymphangiogensis, and suppression of spon-
taneous breast cancer metastasis.
Results
Elimination of CAFs Suppresses Spontaneous Metastasis
and Enhances the Anti-Metastatic Effects of
Chemotherapy
To evaluate the efficacy of pFap vaccination for suppressing
spontaneous breast cancer metastasis, immune competent Balb/c
mice were challenged orthotopically with 4T1 tumor cells and
vaccinated in either a prophylactic (before tumor cell challenge) or
therapeutic (after tumor cell challenge) setting. Additionally, we
also investigated the effects of pFap vaccination when combined
with doxorubicin, a chemotherapeutic drug commonly used in
breast cancer. Prophylactic vaccination with pFap significantly
enhanced the anti-tumor effects of doxorubicin chemotherapy and
suppressed the growth of 4T1 primary tumors in vivo, confirming
our previous findings in non-metastatic tumor models (Figure 1A).
Next, we examined the effect on spontaneous metastasis by
treating mice in a clinically relevant therapeutic model where
therapy was administered after resection of an established primary
tumor. In this therapeutic setting, the addition of pFap vaccination
to doxorubicin chemotherapy significantly increased the life span
of mice with spontaneous metastatic disease (Figure 1B). Addi-
tionally, hematoxylin and eosin staining of lungs from treated mice
showed that the pFap vaccine markedly enhanced the anti-
metastatic effects of doxorubicin chemotherapy as evidenced by
the reduction in metastatic foci (Figure 1C). In contrast, either
pFap vaccination or chemotherapy alone only modestly sup-
pressed spontaneous metastasis though neither was as effective as
the combination therapy. A comparison of the respective
metastatic surface areas revealed that our combination therapy
significantly reduced metastatic load compared to all control
groups (Figure 1D). These data demonstrate that eliminating
CAFs with our pFap vaccine suppresses spontaneous metastasis
and markedly enhances the anti-metastatic effects of doxorubicin
chemotherapy in a 4T1 murine breast cancer model.
Th2 to Th1 Cytokine Transition, CTL Activation and
Tumor Cell Killing in Primary Tumors Following
Combination Therapy
Cell-mediated immunity is associated with Th1 polarization and
generally favors tumor rejection as a result of anti-tumor CTL
responses [13]. In contrast, Th2 cytokine polarization, which is
most commonly associated with solid tumors, generally prevents
tumor rejection and promotes tumor growth [13]. Since Th1
versus Th2 polarization is determined in part by cytokines in the
TME, we investigated the expression of known Th1 and Th2
cytokines by immunoblotting of whole tumor extracts. Western
blotting showed that pFap vaccination markedly increased IL-2
and IL-7 Th1 cytokine expression in primary tumors (Figure 2B).
In contrast, the doxorubicin-induced reduction of IL-6 and IL-4
Th2 cytokine expression in the TME was enhanced by pFap
vaccination (Figure 2A).
Analysis of live tumor homogenates by flow cytometry revealed
that the shift from Th2 to Th1 cytokine expression correlated with
a significant increase in the relative percentage of activated CD8
+/
CD25
+ T cells in the TME (Figure 2C). Additionally, CD8
+ T cells
isolated from spleens of mice treated with our combination
therapy showed enhanced Granzyme B production following
stimulation with irradiated 4T1 cells ex vivo, thus demonstrating an
improved anti-tumor CTL memory effect (Figure 2D). TUNEL
immunohistochemistry, performed on primary tumor sections also
revealed that our combination therapy resulted in significant
increases in the percentage of apoptotic tumor cells 16-days after
cessation of treatment (Figure 2E). Further immunohistochemical
analysis of primary tumors also revealed a marked increase in
association between CD8
+ T cells and caspase 3
+ tumor cells
following treatment with the combination therapy (Figure 2F).
Collectively, these results demonstrate that the pFap vaccine,
when combined with doxorubicin chemotherapy, results in a shift
in cytokine polarization in the TME from Th2 to Th1 and
consequently enhances CTL-associated tumor cell killing in
primary breast tumors.
Elimination of CAFs Reduces Recruitment of Immune
Suppressor Cells and Enhances Immune Effector Cell
Recruitment to Primary Tumors
Tumor infiltrating immune cells such as tumor associated
macrophages (TAMs) and myeloid derived suppressor cells
(MDSCs) are key producers of Th2 cytokines and other factors
that suppress host anti-tumor immune responses while promoting
tumor growth [2]. To determine if the shift from Th2 to Th1
cytokine polarization induced by our combination therapy
correlated with changes in the immune cell milieu of the TME,
we used immunohistochemistry to identify tumor associated
macrophages (TAMs), myeloid derived suppressor cells (MDSCs),
T regulatory cells (Tregs), dendritic cells (DCs) and CD8
+ T cells
in primary tumors. Importantly, vaccination with pFap markedly
reduced the staining in the TME for F4/80
+ TAMs (Figure 3A),
CD11b
+/Gr-1
+ MDSCs (Figure 3B), and CD4
+/FOXP3
+ Tregs
(Figure 3C). In contrast, pFap vaccination markedly enhanced
doxorubicin-associated increases in staining for DCs (Figure 3D)
and CD8
+ T cells (Figure 3E) in the TME. These results
demonstrate that CAFs are key modulators of the immune cell
milieu in the TME and vaccination with pFap can effectively
suppress recruitment of pro-tumor immune cells while enhancing
chemotherapy-induced recruitment of anti-tumor immune cells.
Combination Therapy Inhibits Tumor Angiogenesis and
Lymphangiogenesis and Reduces Vegf, Pdgfc, and GM-
CSF Expression by the TME
Cells prominent in the tumor stroma, including CAFs and
TAMs, produce growth factors and cytokines that support tumor
growth and facilitate metastasis by promoting angiogenesis
[14,15,16]. Therefore, we next determined the effects of pFap
vaccine-induced immune modulation on the expression of pro-
angiogenesis factors in the TME. First, qRT-PCR analysis of
stroma and tumor cell mRNA from primary tumors showed that
Tumor Immune Modulation by CAF
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GM-CSF (Figure 4C) was highest in the tumor stroma. However,
the expression of these growth factors was reduced by pFap
vaccination. In concordance with our mRNA data, Western blot
analysis of tumor extracts demonstrated that the protein level of
these factors was also markedly reduced by our combination
therapy (Figure 4A–C). Additionally, pFap vaccination distinctly
enhanced the chemotherapy-induced reduction of both VEGF as
well as GM-CSF mRNA and protein expression.
Finally, we determined that differences in Vegf, Pdgf, and
GM-CSF gene expression induced by our combination therapy
resulted in changes to tumor vascularization. Blood and lymph
vessels were visualized by immunohistochemistry with CD31 and
LYVE1 antibodies, respectively, and staining for both was
greatly reduced in primary tumors by pFap vaccination
(Figure 5). These results demonstrate that immune modulation
of the TME as a result of pFap vaccination can effectively
suppress tumor angiogenesis and lymphangiogenesis by reducing
stroma-associated expression of pro-angiogenesis growth factors
and cytokines.
Discussion
Our findings reported here demonstrate that CAFs promote
tumor growth and metastasis through their role as key modulators
of immune polarization in the TME (Figure 6). We demonstrated
Figure 1. Vaccination with pFap enhances the anti-metastaic effects of doxorubicin chemotherapy. (A) Mice were treated in a
prophylactic setting and sacrificed 25 days after tumor cell challenge. Primary tumors were resected and their weight (TW) was compared to body
weight (BW) to calculate tumor burden. (B) Mice were treated in a therapeutic setting where primary tumors were allowed to establish prior to
resection and treatment with the combination therapy. Survival of mice after tumor resection was measured using Kaplan-Meier survival curves. *,
p,0.05. (C) Lungs were isolated from moribund mice treated in a therapeutic setting. To visualize metastatic foci, lungs were sectioned and stained
with hematoxylin and eosin. Scale bar=1 mm. (D) Surface areas (SA) of metastatic foci and lung were measured using ImageJ software (n=5 mice/
group). Results are depicted as percent SA
metastasis/SA
lung. ***, p,0.0005.
doi:10.1371/journal.pone.0007965.g001
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PLoS ONE | www.plosone.org 3 November 2009 | Volume 4 | Issue 11 | e7965Figure 2. Vaccination with pFap results in Th2 to Th1 cytokine transition in the tumor microenvironment. Mice were treated in a
prophylactic setting and primary tumors isolated 25 days later. (A–B) Tumor homogenates were analyzed by Western blotting to determine IL-6 and
IL4 (A) and IL-2 and IL-7 (B) protein levels. (C) Live primary tumor cell suspensions were analyzed by flow cytometry using anti-CD8 and anti-CD25
antibodies to detect activated T-cells. Results are shown as percent of CD8
+/CD25
+ T cells relative to mice treated with the combination therapy. (D)
Splenocytes were isolated from tumor bearing mice treated with the combination therapy or controls. Splenocytes were stimulated twice with IL-2
and then incubated with irradiated 4T1 tumor cells for 24 hours prior to detection of CD8
+/Granzyme B
+ cells by flow cytometry. (E) Primary tumors
were isolated from mice treated in a prophylactic setting 10-days after the final treatment with doxorubicin and apoptotic tumor cells were visualized
by quantified using the TUNEL assay. (F) Additionally, we also used immunohistochemistry to visualize CD8
+ T cells (red) and apoptotic tumor cells
expressing caspase 3 (green) in primary tumors. Scale bar=100 mm.
doi:10.1371/journal.pone.0007965.g002
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PLoS ONE | www.plosone.org 4 November 2009 | Volume 4 | Issue 11 | e7965Figure 3. Vaccination with pFap suppresses TAM, MDSC, Treg, and enhances DC and CTL recruitment. Primary tumors were isolated
from mice 25 days after orthotopic challenge and immune cells were identified in primary tumors using antibodies for the following: (A) tumor-
associated macrophages (TAMs): F4/80 (red), (B) myeloid derived suppressor cells (MDSCs): CD11b (red, nuclear) and Gr-1 (green, nuclear), (C) T
regulatory cells (Tregs, white arrowheads): CD4 (red, cell surface) and FOXP3 (green, nuclear), (D) dendritic cells (DC): 33D1 (red), and (E) cytotoxic T
lymphocytes (CTL): CD8 (red) Scale bar for all panels=100 mm.
doi:10.1371/journal.pone.0007965.g003
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recruitment of pro-tumor immune cells and correlated with an
increase in Th1 cytokine expression in the TME. Additionally,
pFap vaccination reduced stroma-associated expression of pro-
angiogenesis factors and effectively suppressed tumor angiogenesis
and lymphangiogenesis. Finally, the shift in Th2 to Th1 cytokine
polarization induced by pFap vaccination significantly enhanced
the anti-metastatic effects of doxorubicin chemotherapy. Collec-
tively, this report adds new information to the growing evidence
supporting an integral role for the TME in promoting cancer
Figure 4. Combination therapy reduces tumor associated Vegf, Pdgfc, and GM-CSF mRNA and protein expression. Tumors were
isolated 25 days after orthothopic challenge and total RNA was isolated from the stroma (S) and tumor cells (TC) by laser capture dissection
microscopy, and used to generate cDNA for qRT-PCR analysis. Gene expression is normalized to actin and shown relative to stroma of vector control
for Vegfa, Pdgfc, and GM-CSF (A–C, left panel, respectively). *, p,0.05, **, p,0.005. Whole cell extracts were derived from primary tumors and
subjected to immunoblotting to detect Vegf, Pdgfc and GM-CSF protein and detection of actin was used as a loading control (A–C, right panel,
respectively).
doi:10.1371/journal.pone.0007965.g004
Tumor Immune Modulation by CAF
PLoS ONE | www.plosone.org 6 November 2009 | Volume 4 | Issue 11 | e7965Figure 5. Vaccination with pFap suppresses tumor angiogenesis and lymphangiogenesis. Mice were treated with vector control (A), pFap
(B), doxorubicin (C), or pFap plus doxorubicin (D). Primary tumors were isolated from mice 25 days after orthotopic challenge. Tumor sections were
treated with anti-CD31 and anti-LYVE1 antibodies to detect blood (brown) and lymph (green) vessels, respectively. Scale bar=100 mm.
doi:10.1371/journal.pone.0007965.g005
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as a therapeutic target for breast cancer.
These conclusions are further supported by reports of others
indicating that cells in the TME influence tumor progression and
metastasis through production of growth factors and cytokines that
modulate these processes [6,17]. Importantly in this regard, treatment
with our combination therapy mediated a transition in the TME from
a Th2 to Th1 polarization through reductions in IL-6 and IL-4 and
increases in IL-2 and IL-7 cytokine expression. This finding is
particularly significant since increased levels of IL-6 in tissues and
serum has been shown to correlate with poorprognosis in breast cancer
patients [18]. However, what effects our combination therapy has on
expression levels of such cytokines as IL-6 in the serum of tumor
bearing mice in our model remains to be determined. Regardless, in
the context of the TME, IL-6 mediated cross-talk between stromal
fibroblasts and monocytes was shown to promote the differentiation of
monocytes into macrophages at the expense of DCs [19]. Additionally,
receptors for IL-4 are expressed by many human tumor types and have
been shown to promote the proliferation of tumor cells [20]. In
contrast, Th1 cytokines IL-2 and IL-7 are potent stimulators of T-cell
cytotoxic activity and of memory CD8
+ T cell survival, respectively,
both of which are critical for effective tumor immunotherapy [21,22].
Intriguingly, splenocytes isolated from tumor bearing mice treated with
our combination therapy showed an enhanced anti-tumor CTL
response when exposed to irradiated 4T1 tumor cells ex vivo,t h u s
demonstrating improved T-cell memory.
Importantly, Th2 cytokine polarization is also commonly
associated with an angiogenesis phenotype [23], which is critical
for sustained tumor growth and promotes dissemination of tumor
cells [24]. Significantly, we found that expression of Vegf, Pdgfc,
and GM-CSF in primary tumors was markedly reduced at both
the mRNA and protein levels by treatment with our combination
therapy. In this setting, paracrine VEGF signaling between tumor
cells and the tumor stroma was reported to contribute to the
recruitment of endothelial and lymphatic progenitors required for
tumor angiogenesis and lymphangiogenesis [7]. Intriguingly,
increased Pdgfc expression by CAFs caused resistance to anti-
VEGF therapy in EL4 lymphoma [25], a relevant finding since
our combination therapy also significantly decreased mRNA and
protein expression of both Vegf and Pdgfc by the tumor stroma.
Likewise, Pdgfc participated in a paracrine signaling network that
accelerated tumor growth through recruitment of reactive stromal
cells in malignant melanoma [26]. Additionally, GM-CSF also
promotes migration and proliferation of endothelial cells [27].
We could further demonstrate that in primary tumors, pFap
vaccination markedly suppressed recruitment of TAMs, MDSCs,
and Tregs to the TME. These three cell types have all been
identified in human malignancies and their pro-tumor and
immune suppressive effects are well documented
[28,29,30,31,32]. Additionally, both TAMS and MDSCs can
promote the survival and invasiveness of cancer cells through
secretion of growth factors and proteases [32,33]. In contrast,
Tregs directly inhibit the activation of CD8
+ cytotoxic T cells thus
reducing effective killing of tumor cells [34,35].
Conversely, we found that pFap vaccination markedly
enhanced doxorubicin-induced recruitment of DCs and CD8
+ T
cells to the TME. In this regard, DCs are of particular importance
since they have been shown to directly stimulate CTLs by cross
presentation of apoptotic tumor cell antigens [36,37]. Intriguingly,
doxorubicin itself can also induce immunogenic cell death by a
process that depends on the phagocytic uptake of apoptotic tumor
cells by local DCs and subsequent priming of CD8
+ T cells
[38,39,40]. Importantly, our combination therapy markedly
increased the presence of DCs and activated CD8
+ T cells in
primary tumors.
Based on our findings, the anti-metastatic effects of our
combination therapy are attributable to remodeling of the TME
as a result of CAF clearance in addition to killing of tumor cells. As
illustrated in Figure 6, the resulting modulation of the immune cell
and cytokine milieu in the TME ultimately tips the balance in
favor of an anti-tumor response. This reasoning could explain why
maximum anti-metastatic effects are achieved when both CAFs
and tumor cells are targeted for elimination.
This conclusion holds important implications for future
applications of immunotherapy to treat human malignancies. In
this regard, tumor cells are inherently immunogenic due to
expression of tumor-associated antigens (TAAs) that can be
targeted by the host immune system through vaccination with
TAAs [35,41]. Although many studies have successfully proven
this concept with in vitro cell-based assays, the same efficacy for
TAA vaccination in the clinical setting has unfortunately not yet
materialized [42]. Based on our findings here, this dichotomy
could be due, in part, to CAF-mediated modulation of the
immune TME in vivo, which is excluded in ex vivo manipulations.
Therefore, it would be intriguing to assess in the future whether
our combination therapy could improve tumor immunosurveil-
lance due to TAA vaccination in vivo. Regardless, our findings raise
the potential that the TME could be optimized for anti-tumor
effects of TAA-based immunotherapy in a clinical setting by prior
treatment with our combination therapy.
Figure 6. Our combination therapy exerts its anti-metastatic
effects through modulation of the immune tumor microenvi-
ronment. Cancer associated fibroblasts (CAFs) promote tumor growth
and metastasis by recruiting tumor associated macrophages (TAMS),
myeloid derived suppressor cells (MDSCs) and T regulatory cells (Tregs)
and promoting Th2 polarization of the tumor microenvironment. This
modulation of the tumor microenvironment results in production of
growth factors and cytokines that support tumor growth and
metastasis by promoting angiogenesis, lymphangiogenesis, and
suppression of anti-tumor immune responses. Elimination of CAFs by
treatment with our pFap vaccine, in combination with doxorubicin
chemotherapy, modulates the immune tumor microenvironment and
shifts polarization from Th2 to Th1, characterized by an increase in
dendritic cells (DCs) and cytotoxic T lymphocytes (CTLs) and Th1
cytokine expression. As a result, tumor angiogenesis and lymphangio-
genesis are reduced and anti-tumor immune responses are enhanced
leading to suppression of spontaneous metastasis of 4T1 breast cancer
cells.
doi:10.1371/journal.pone.0007965.g006
Tumor Immune Modulation by CAF
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Animals, Bacterial Strains, and Cell Lines
Animals were housed in a facility approved by the Association for
Assessment and Accreditation of Laboratory Animal Care Interna-
tional. All animal experiments and protocols were performed
according to the NIH Guide for the Care and Use of Laboratory
Animals and approved by The Scripps Research Institute Animal
Care Committee. Balb/c mice were purchased from The Scripps
Research InstituteRodentBreedingFacility. The doubleattenuated
S. typhimurium strain RE88 (adroA-dam-) is maintained in our
laboratory. Cloning and expression of cDNAs encoding murine
FAP (provided by J.D. Cheng, Department of Medical Oncology,
Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA) in S.
typhimurium was described previously [9]. The 4T1 murine breast
carcinoma cell line was kindly provided by Suzanne Ostrand-
Rosenberg (University of Maryland, College Park, Maryland, USA)
and cultured in RPMI-1640 medium (ATCC) supplemented with
10% fetal bovine serum and 1% sodium bicarbonate.
Tumor Cell Challenge, Immunization, and Doxorubicin
Treatment
For orthotopic tumor cell challenge, the inguinal mammary fat
pads of 3 week old female Balb/c mice were first cleared of host
epithelium as previously described [43]. Mice were then
challenged with 5610ˆ3 4T1 tumor cells by orthotopic injection.
Immunization with S. typhimurium in a prophylactic setting has
been previously described [9]. For immunization in a therapeutic
setting, mice were first challenged orthotopically and primary
tumors were removed 22 d later. Animals were vaccinated twice at
2 d intervals 4 d prior to tumor resection, and then three times at 5
d intervals beginning 2 d after tumor resection. Doxorubicin
(Sigma-Aldrich) was administered by i.v. injection (10 mg/kg), 3
times at 5 d intervals. For experiments performed in either
prophylactic or therapeutic setting, doxorubicin treatment began 5
d after orthotopic challenge and 2 d after tumor resection,
respectively. We used 8 mice per treatment group. Tumor
dimensions were measured twice-weekly using calipers. Tumor
volume was calculated as previously described [9].
LCDM and QRT-PCR
Primary tumors were immediately frozen into O.C.T. Com-
pound (Tissue-Tek) and stored at 280uC. Tumor sections, 8 mm
thick, were stained with a HistoGene LCM Frozen Section
Staining Kit (Arcturus) and tissues captured with an Arcturus
PixCell II Laser Capture Microdissection microscope (Arcturus),
according to the manufacturer’s protocol. Total RNA was isolated
with the PicoPure RNA Isolation Kit (Arcturus) and cDNA
generated using the QuantiTect Whole Transcriptome Kit
(Invitrogen). QRT-PCR was performed with primer sets from
RealTimePrimers.com according to the manufacturer’s protocol.
Gene expression was normalized to b-actin. Results represent data
combined from three different experiments.
Immunohistochemistry
Frozen tumor sections were fixed in cold acetone and blocked in
10% normal goat serum prior to incubation with antibody: rat-
amouse CD8 (AbD Serotec), rat-amouse DCs (BD Pharmingen),
rat-amouse F4/80 (AbD Serotec), and rat-amouse CD4 (BD
Pharmingen), a-mouse FOXP3 (Santa Cruz Biotechnology),
rabbit-amouse LYVE1 (Reliatech), rabbit-amouse CD31 (BD
Pharmingen), and rabbit-amouse Caspase 3 (Santa Cruz Biotech-
nology). Apoptotic tumor cells were detected using the DeadEnd
Colorimetric TUNEL System (Promega). For determination of
percent TUNEL positive cells, a minimum of 9 different fields per
group were counted at 206 magnification for TUNEL positive
cells and total cell number.
Histology of Pulmonary Metastasis
For visualization of pulmonary metastasis, lung tissue was fixed
in 10% phosphate buffered. Lungs were then cut into 20 mm thick
serial sections and stained with hematoxylin and eosin. The
surface area of metastatic foci in lungs (n=6 per group) was
measured using ImageJ software.
Flow Cytometry
Live primary tumor cell suspensions were isolated from tumor
bearing mice and analyzed immediately for activated CD8
+ T cells
with 2-color flow cytometry using a-CD8 antibody (BD Pharmin-
gen) and a-CD25 antibody (BD Pharmingen). Results are
combined from 2 different experiments. To determine anti-tumor
CTL response, splenocytes were cultured for 5 days and
stimulated twice with recombinant IL-2 (50 u/ml) (PeproTech)
and then incubated with 10ˆ6 irradiated 4T1 tumor cells for
24 hours prior to staining with a-CD8 and a-Granzyme B
antibodies, according to the manufacturer’s protocol (BD
Pharmingen), and analysis using flow cytometry. Results are
representative of 2 separate experiments.
Western Blots
Tumor whole cell extracts were generated as previously
described [44] and a-VEGF, a-GM-CSF, a-Pdgfc, aIL-2, aIL-7,
aIL-4, and a-actin (all from Santa Cruz Biotechnology), and aIL-6
(R&D Systems) antibodies were used.
Statistical Analysis
Statistical analysis was done with Prism 5.0 (GraphPad
Software) and Excell (Microsoft) software. Statistical significance
was determined by student’s t test (significance when p,0.05).
Survival curves were analyzed by the Kaplan-Meier survival
method, and statistical significance was determined using the log-
rank test (significance when p,0.05).
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